Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Akebia Therapeutics (AKBA) Cost of Revenue: 2018-2024

Historic Cost of Revenue for Akebia Therapeutics (AKBA) over the last 7 years, with Dec 2024 value amounting to $63.2 million.

  • Akebia Therapeutics' Cost of Revenue fell 33.74% to $9.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $47.3 million, marking a year-over-year decrease of 23.07%. This contributed to the annual value of $63.2 million for FY2024, which is 14.80% down from last year.
  • Per Akebia Therapeutics' latest filing, its Cost of Revenue stood at $63.2 million for FY2024, which was down 14.80% from $74.1 million recorded in FY2023.
  • In the past 5 years, Akebia Therapeutics' Cost of Revenue registered a high of $296.5 million during FY2020, and its lowest value of $63.2 million during FY2024.
  • Moreover, its 3-year median value for Cost of Revenue was $74.1 million (2023), whereas its average is $74.3 million.
  • In the last 5 years, Akebia Therapeutics' Cost of Revenue spiked by 103.99% in 2020 and then tumbled by 49.18% in 2021.
  • Over the past 5 years, Akebia Therapeutics' Cost of Revenue (Yearly) stood at $296.5 million in 2020, then tumbled by 49.18% to $150.7 million in 2021, then crashed by 43.21% to $85.6 million in 2022, then decreased by 13.34% to $74.1 million in 2023, then fell by 14.80% to $63.2 million in 2024.